TWD 79.5
(-3.52%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 553.58 Million TWD | 14.46% |
2022 | 482.25 Million TWD | 2.27% |
2021 | 471.53 Million TWD | 13.63% |
2020 | 414.95 Million TWD | 0.39% |
2019 | 413.35 Million TWD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 139.07 Million TWD | -6.31% |
2024 Q2 | 144.04 Million TWD | 2.64% |
2023 Q4 | 148.44 Million TWD | -0.75% |
2023 FY | 551.98 Million TWD | 14.46% |
2023 Q3 | 149.57 Million TWD | 10.57% |
2023 Q2 | 135.28 Million TWD | 13.99% |
2023 Q1 | 118.67 Million TWD | -10.63% |
2022 FY | 482.25 Million TWD | 2.27% |
2022 Q4 | 132.79 Million TWD | 0.0% |
2021 FY | 471.53 Million TWD | 13.63% |
2020 FY | 414.95 Million TWD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
DIVA Laboratories, Ltd. | 158.62 Million TWD | -248.998% |
Genetics Generation Advancement Corp. | 218.25 Million TWD | -153.642% |
Welgene Biotech Co.,Ltd. | 123.97 Million TWD | -346.529% |
Puriblood Medical Co., Ltd. | 56.92 Million TWD | -872.462% |
TFBS Bioscience Inc. | 77.82 Million TWD | -611.282% |